Boston Scientific has completed first patient enrolment in a prospective randomised international neural cardiac therapy for heart failure (NECTAR-HF) clinical trial.

The clinical feasibility study will evaluate 96 patients with vagal nerve stimulator implants to study the preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients.

The first implants in the trial took place at Hospital Clinic in Barcelona, Spain.

Barcelona’s Hospital Clinic medical director Josep Brugada said NECTAR-HF will investigate whether vagal nerve stimulation can restore autonomic balance and therefore improve heart function, increase exercise capacity and inhibit progression of heart failure.

Boston Scientific Cardiac Rhythm Management chief medical officer Kenneth Stein said this novel technology utilises Boston Scientific’s capabilities in cardiac rhythm management device therapy, lead technologies and neuromodulation.

”This treatment capability illustrates our strategy to offer new therapies in high-potential markets that are designed to improve the quality of life for patients," Stein added.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.